Syndromes - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Syndromes

JAGX, NASDAQ, Tickers

#New Employee #Syndromes

Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics

January 24, 2022
08:30

EST

Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases – beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has been granted Orphan-Drug Designation for crofelemer by the European Medicines Agency, and Jaguar Health has been granted Orphan-Drug Designation

No Comments

NASDAQ, SLNO, Tickers

#Letter to Shareholders #Syndromes

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

January 24, 2022
08:00

EST

REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development

No Comments

NASDAQ, Tickers, ZGNX

#Analyst Update #Syndromes #Third-Party Article

Zogenix Stock (ZGNX): $26 Price Target From Northland

January 22, 2022
21:18

EST

The shares of Zogenix, Inc. (NASDAQ: ZGNX) have received a price target of $26 from Northland. These are the details. The shares of Zogenix, Inc. (NASDAQ: ZGNX) have received a price target of $26 from Northland. And Northland analyst Carl Byrnes adjusted the price target from $32 while maintaining

No Comments

KURA, NASDAQ, Tickers

#FDA #Phase 1 #Syndromes

Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

January 20, 2022
16:01

EST

– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed among patients on study – SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) — Kura

No Comments

NASDAQ, Tickers, ZEAL

#Phase 3: Enrollment Complete #Positive Clinical Trial Results #Syndromes

Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

January 20, 2022
07:30

EST

Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022 Pending positive pivotal data, Zealand intends to file for marketing approval

No Comments

NASDAQ, OTC, Tickers, UCBJF, ZGNX

#Syndromes

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

January 19, 2022
06:08

EST

Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy. Investors will get in cash for every Zogenix share, plus a potential $2 per share payment

No Comments

AMEX, CHMP, CVR, NASDAQ, OTC, Tickers, TO, ZGNX

#Featured #Syndromes

UCB to acquire Zogenix

January 19, 2022
01:00

EST

BRUSSELS and EMERYVILLE, Calif., Jan. 19, 2022 /PRNewswire/ — Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare

No Comments

LVTX, NASDAQ, Tickers

#Conference #New Clinical Trial Data #Syndromes

LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference

January 18, 2022
08:30

EST

The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome (CRS), potentially translating in a superior therapeutic index compared to CD3-based T cell engagers New non-human primate data

No Comments

ACHC, NASDAQ, Tickers, XERS

#New Order #Syndromes

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome

January 13, 2022
08:55

EST

PITTSBURGH, Jan. 13, 2022 /PRNewswire/ — PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole). Recorlev is a cortisol synthesis inhibitor indicated for

No Comments

JAGX, NASDAQ, Tickers

#Corporate Presentation #Syndromes

Jaguar Health Provides Corporate Update and Outlines 2022 Milestones

January 13, 2022
08:30

EST

2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure (SBS-IF) and received conditional approval for Canalevia™-CA1 (crofelemer) for dogs Pipeline advancing in 2022 with company’s Phase 3 CTD

No Comments

< Page1 … Page56 Page57 Page58 Page59 Page60 … Page66 >

Trending News

Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

05/26/2023

SILVERCORP DECLARES SEMI-ANNUAL DIVIDEND OF US$0.0125 PER SHARE

05/26/2023

Halo Collective Provides Update on Status of Financial Statements

05/26/2023

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/26/2023

US Investors May Now Have Trading Access for Genius Group Shares on Upstream through US Broker Dealer

05/26/2023

Most read news

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn’s Disease

05/25/2023

Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.

05/24/2023

Avante Announces Private Placement Closing

05/24/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account